Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

12. November 2026 aktualisiert von: Cugene Inc.

A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.

Studienübersicht

Status

Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion

Studientyp

Interventionell

Einschreibung (Geschätzt)

65

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Virginia
      • Fairfax, Virginia, Vereinigte Staaten, 22031
        • Rekrutierung
        • NEXT Virginia

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Signed and dated informed consent.
  2. Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
  3. At least 1 measurable lesion according to RECIST v1.1.
  4. Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  6. Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
  7. Life expectancy of ≥3 months.
  8. Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.

Exclusion Criteria

  1. Rapidly progressing disease or disease requiring urgent alternative medical intervention.
  2. Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
  3. Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
  4. Concurrent participation in another interventional therapeutic clinical trial.
  5. Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
  6. Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
  7. Unresolved clinically significant toxicities from prior anticancer therapy.
  8. Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
  9. Active or clinically significant infection except as specified in the protocol.
  10. Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
  11. Known hypersensitivity or significant allergic reaction to biologics or its components.
  12. Recent vaccination, except as permitted by the protocol.
  13. Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Part A Dose Escalation

CUG279 will be administered at multiple ascending dose levels

CUG279 will be administered intravenously according to the protocol

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of dose limiting toxicities (DLTs)
Zeitfenster: From the first dose up to 21 days post-dose

The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A.

From the first dose up to 21 days post-dose
Incidence and severity of treatment-emergent adverse events (TEAEs)
Zeitfenster: From first dose through 90 days after the last dose

The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of serious adverse events (SAEs)
Zeitfenster: From first dose through 90 days after the last dose

The number and percentage of participants with SAEs will be assessed.

From first dose through 90 days after the last dose
Clinically significant changes in safety laboratory parameters from baseline
Zeitfenster: From first dose through 90 days after the last dose

Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in electrocardiogram (ECG) findings from baseline
Zeitfenster: From first dose through 90 days after the last dose

Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in vital signs from baseline
Zeitfenster: From first dose through 90 days after the last dose

Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of TEAEs leading to dose modifications
Zeitfenster: From the first dose through the last dose; up to 1 year

The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed.

From the first dose through the last dose; up to 1 year

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum observed plasma concentration (Cmax) of CUG279
Zeitfenster: From first dose through 90 days after the last dose

The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Trough plasma concentrations (Ctrough) of CUG279
Zeitfenster: From first dose through 90 days after the last dose

The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose

From first dose through 90 days after the last dose
Area under the concentration-time curve (AUC) of CUG279
Zeitfenster: From first dose through 90 days after the last dose

The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data.

From first dose through 90 days after the last dose
Terminal half-life (T1/2) of CUG279
Zeitfenster: From first dose through 90 days after the last dose

The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Systemic clearance (CL) of CUG279
Zeitfenster: From first dose through 90 days after the last dose

The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Volume of distribution (Vz) of CUG279
Zeitfenster: From first dose through 90 days after the last dose

The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 antibodies (ADA)
Zeitfenster: From first dose through 90 days after the last dose

Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 neutralizing antibodies (NAb)
Zeitfenster: From first dose through 90 days after the last dose

Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined

From first dose through 90 days after the last dose
Objective response rate (ORR)
Zeitfenster: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Disease control rate (DCR)
Zeitfenster: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Time to response (TTR)
Zeitfenster: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1

From the first dose through study completion or until disease progression; up to 1 year
Duration of response (DoR)
Zeitfenster: From the first dose through study completion or until disease progression; up to 1 year

Time from first documented CR or PR to disease progression will be determined per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Best overall response (BOR)
Zeitfenster: From the first dose through study completion or until disease progression; up to 1 year

Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Progression-free survival (PFS)
Zeitfenster: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

5. November 2026

Primärer Abschluss (Geschätzt)

30. März 2029

Studienabschluss (Geschätzt)

30. März 2029

Studienanmeldedaten

Zuerst eingereicht

19. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CUG279-P101
  • IND 179862 (U.S. FDA IND) (Andere Kennung: FDA)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren